Machine Learning Approach Predicts Probability of Time to Stage-Specific Conversion of Alzheimer's Disease
- PMID: 36189595
- PMCID: PMC9840816
- DOI: 10.3233/JAD-220590
Machine Learning Approach Predicts Probability of Time to Stage-Specific Conversion of Alzheimer's Disease
Abstract
Background: The progression of Alzheimer's disease (AD) varies in different patients at different stages, which makes predicting the time of disease conversions challenging.
Objective: We established an algorithm by leveraging machine learning techniques to predict the probability of the conversion time to next stage for different subjects during a given period.
Methods: Firstly, we used Kaplan-Meier (KM) estimation to get the transition curves of different AD stages, and calculated Log-rank statistics to test whether the progression rate between different stages was identical. This quantitatively confirmed the progression rates known in the literature. Then, we developed an approach based on deep learning model, DeepSurv, to predict the probabilities of time-to-conversion. Finally, to help interpret the deep learning model in our approach, we identified important variables contributing the most to the DeepSurv prediction, whose significance were validated with the analysis of variance (ANOVA).
Results: Our machine learning approach predicted the time to conversion with a high accuracy. For each of the different stages, the concordance index (CI) of our approach was at least 86%, and the integrated Brier score (IBS) was less than 0.1. To facilitate interpretability of the prediction results, our approach identified the top 10 variables for each disease conversion scenario, which were clinicopathologically meaningful, and most of them were also statistically significant.
Conclusion: Our study has the potential to provide individualized prediction for future time course of AD conversions years before their actual occurrence, thus facilitating personalized prevention and intervention strategies to slow down the progression of AD.
Keywords: Analysis of variance; dementia; machine learning; survival analysis.
Figures




Similar articles
-
Deep learning algorithm reveals probabilities of stage-specific time to conversion in individuals with neurodegenerative disease LATE.Alzheimers Dement (N Y). 2022 Nov 3;8(1):e12363. doi: 10.1002/trc2.12363. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 36348767 Free PMC article.
-
A Machine Learning-Based Holistic Approach to Predict the Clinical Course of Patients within the Alzheimer's Disease Spectrum.J Alzheimers Dis. 2022;85(4):1639-1655. doi: 10.3233/JAD-210573. J Alzheimers Dis. 2022. PMID: 34958014
-
Development and validation of machine learning models for predicting prognosis and guiding individualized postoperative chemotherapy: A real-world study of distal cholangiocarcinoma.Front Oncol. 2023 Mar 15;13:1106029. doi: 10.3389/fonc.2023.1106029. eCollection 2023. Front Oncol. 2023. PMID: 37007095 Free PMC article.
-
Machine Learning Algorithms and Statistical Approaches for Alzheimer's Disease Analysis Based on Resting-State EEG Recordings: A Systematic Review.Int J Neural Syst. 2021 May;31(5):2130002. doi: 10.1142/S0129065721300023. Epub 2021 Feb 16. Int J Neural Syst. 2021. PMID: 33588710
-
Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease.Int J Mol Sci. 2021 Mar 9;22(5):2761. doi: 10.3390/ijms22052761. Int J Mol Sci. 2021. PMID: 33803217 Free PMC article.
Cited by
-
Identification of profiles associated with conversions between the Alzheimer's disease stages, using a machine learning approach.Alzheimers Res Ther. 2024 Jul 26;16(1):166. doi: 10.1186/s13195-024-01533-5. Alzheimers Res Ther. 2024. PMID: 39061107 Free PMC article.
-
Random survival forest model for early prediction of Alzheimer's disease conversion in early and late Mild cognitive impairment stages.PLoS One. 2024 Dec 13;19(12):e0314725. doi: 10.1371/journal.pone.0314725. eCollection 2024. PLoS One. 2024. PMID: 39671432 Free PMC article.
References
-
- Mucke L (2009) Alzheimer’s disease. Nature 461, 895–897. - PubMed
-
- Anderson ND (2019) State of the science on mild cognitive impairment (MCI). CNS Spectrums 24, 78–87. - PubMed
-
- Chui HC (1987) The significance of clinically defined subgroups of Alzheimer’s disease. J Neural Transm Suppl 24, 57–68. - PubMed
Publication types
MeSH terms
Grants and funding
- P30 AG072946/AG/NIA NIH HHS/United States
- P50 AG005142/AG/NIA NIH HHS/United States
- P50 AG016573/AG/NIA NIH HHS/United States
- P50 AG047266/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- P50 AG025688/AG/NIA NIH HHS/United States
- R21 AG070909/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- P50 AG005138/AG/NIA NIH HHS/United States
- P50 AG047366/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- P30 AG028383/AG/NIA NIH HHS/United States
- P50 AG033514/AG/NIA NIH HHS/United States
- P30 AG013854/AG/NIA NIH HHS/United States
- P30 AG053760/AG/NIA NIH HHS/United States
- R56 NS117587/NS/NINDS NIH HHS/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- P50 AG005131/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- P50 AG005146/AG/NIA NIH HHS/United States
- U24 AG072122/AG/NIA NIH HHS/United States
- P30 AG035982/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P30 AG013846/AG/NIA NIH HHS/United States
- P50 AG047270/AG/NIA NIH HHS/United States
- P50 AG005136/AG/NIA NIH HHS/United States
- P30 AG049638/AG/NIA NIH HHS/United States
- P30 AG012300/AG/NIA NIH HHS/United States
- P50 AG005134/AG/NIA NIH HHS/United States
- P30 AG008017/AG/NIA NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- P30 AG072947/AG/NIA NIH HHS/United States
- R01 HD101508/HD/NICHD NIH HHS/United States
- P41 RR000954/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical